Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. METHO...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:RMD Open
Auteurs principaux: Cohen, Stanley B, Tanaka, Yoshiya, Mariette, Xavier, Curtis, Jeffrey R, Lee, Eun Bong, Nash, Peter, Winthrop, Kevin L, Charles-Schoeman, Christina, Wang, Lisy, Chen, Connie, Kwok, Kenneth, Biswas, Pinaki, Shapiro, Andrea, Madsen, Ann, Wollenhaupt, Jürgen
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2020
Sujets:
Rheumatoid Arthritis
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722371/
https://ncbi.nlm.nih.gov/pubmed/33127856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001395
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires